Group 1 - Top Wall Street analysts have revised their outlook on several prominent companies, indicating a shift in market sentiment [1] - Analysts are considering ULTA stock as a potential buy, reflecting positive sentiment towards the company's future performance [1]

Core Insights - Dole reported quarterly earnings of $0.16 per share, missing the Zacks Consensus Estimate of $0.17 per share, and down from $0.19 per share a year ago, representing an earnings surprise of -5.88% [1] - The company posted revenues of $2.28 billion for the quarter ended September 2025, surpassing the Zacks Consensus Estimate by 1.33%, and up from $2.06 billion year-over-year [2] - Dole shares have underperformed the market, losing about 3% since the beginning of the year compared to the S&P 500's gain of 14.4% [3] Earnings Outlook - The current consensus EPS estimate for the coming quarter is $0.16 on revenues of $2.29 billion, and for the current fiscal year, it is $1.03 on revenues of $9.07 billion [7] - The estimate revisions trend for Dole was mixed ahead of the earnings release, resulting in a Zacks Rank 3 (Hold) for the stock, indicating expected performance in line with the market [6] Industry Context - The Agriculture - Operations industry, to which Dole belongs, is currently in the bottom 17% of over 250 Zacks industries, suggesting potential challenges for stock performance [8] - Empirical research indicates a strong correlation between near-term stock movements and trends in earnings estimate revisions, which can be tracked by investors [5]

Core Insights - Bioceres Crop Solutions Corp. is a leader in developing and commercializing productivity solutions aimed at regenerating agricultural ecosystems and enhancing crop resilience to climate change [1] Company Information - The company will hold a conference call on November 13, 2025, at 8:30 a.m. Eastern Time to discuss its fiscal first quarter results for the period ending September 30, 2025 [1] - A press release detailing the financial results will be issued prior to the conference call [1]

Group 1 - Lake Street analyst Ben Klieve lowered the price target on Bioceres (BIOX) to $5 from $8 while maintaining a Buy rating on the shares [1] - Q4 results were significantly below all estimates across each segment, indicating potential challenges for the company [1] - The firm anticipates that FY25 will represent an EBITDA trough and sees value in the next-generation products within Bioceres' portfolio [1]

Analyst Downgrades - Canaccord Genuity analyst Austin Moeller downgraded Bioceres Crop Solutions Corp. from Buy to Hold, lowering the price target from $6.5 to $2.5, with shares closing at $2.24 [6] - Compass Point analyst Floris Van Dijkum downgraded BXP, Inc. from Buy to Neutral, setting a price target of $75, with shares closing at $72.40 [6] - UBS analyst Manav Gupta downgraded Hess Midstream LP from Buy to Neutral, reducing the price target from $45 to $43, with shares closing at $40.70 [6] - Berenberg analyst Fulvio Cazzol downgraded Coty Inc. from Buy to Hold, lowering the price target from $6.5 to $5.05, with shares closing at $4.25 [6] - Evercore ISI Group analyst Amit Daryanani downgraded HP Inc. from Outperform to In-Line, maintaining a price target of $29, with shares closing at $29.04 [6]

Group 1: Earnings Performance - Cibus reported a quarterly loss of $0.74 per share, which was worse than the Zacks Consensus Estimate of a loss of $0.70, but an improvement from a loss of $1.12 per share a year ago, indicating a year-over-year improvement [1] - The company posted revenues of $1.03 million for the quarter, missing the Zacks Consensus Estimate by 12.37%, but showing an increase from $0.55 million in the same quarter last year [2] - Over the last four quarters, Cibus has surpassed consensus EPS estimates only once, while it has topped consensus revenue estimates three times [2] Group 2: Stock Performance and Outlook - Cibus shares have declined approximately 10.1% since the beginning of the year, compared to a decline of 4.3% for the S&P 500 [3] - The company's earnings outlook is crucial for investors, as it includes current consensus earnings expectations for upcoming quarters and any recent changes to those expectations [4] - The current consensus EPS estimate for the next quarter is -$0.68 on revenues of $1.2 million, and for the current fiscal year, it is -$2.66 on revenues of $9.93 million [7] Group 3: Industry Context - The Agriculture - Operations industry, to which Cibus belongs, is currently ranked in the top 38% of over 250 Zacks industries, suggesting a favorable industry outlook [8] - Empirical research indicates a strong correlation between near-term stock movements and trends in earnings estimate revisions, which can be tracked by investors [5] - Another company in the same industry, Bioceres Crop, is expected to report a quarterly loss of $0.10 per share, reflecting a significant year-over-year decline [9]

As filed with the Securities and Exchange Commission on April 17, 2023 Registration No. 333- UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM F-1 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 If this Form is filed to register additional securities for an offering pursuant to Rule 462(b) under the Securities Act, check the following box and list the Securities Act registration statement number of the earlier effective registration statement for the same offering. ☐ If th ...

As filed with the Securities and Exchange Commission on March 22, 2023 Registration No. 333-269439 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Amendment No. 2 to ____________________ FORM F-1 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 ____________________ Moolec Science SA (Exact Name of Registrant as Specified in Its Charter) ____________________ | Grand Duchy of Luxembourg 1119 | Not Applicable | | --- | --- | | (Jurisdiction of (Primary Standard Industrial | (I.R. ...

As filed with the Securities and Exchange Commission on March 17, 2023 Registration No. 333-269439 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Amendment No. 1 to ____________________ FORM F-1 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 ____________________ Moolec Science SA (Exact Name of Registrant as Specified in Its Charter) ____________________ | Grand Duchy of Luxembourg | 1119 | Not Applicable | | --- | --- | --- | | (Jurisdiction of | (Primary Standard Industri ...

(Exact Name of Registrant as Specified in Its Charter) ____________________ As filed with the Securities and Exchange Commission on January 27, 2023 Registration No. 333- UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 ____________________ FORM F-1 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 ____________________ Moolec Science SA | Grand Duchy of Luxembourg | 1119 | Not Applicable | | --- | --- | --- | | (Jurisdiction of | (Primary Standard Industrial | (I.R.S. Employer | ...